Skip to main navigation Skip to search Skip to main content

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib

  • N. Elster
  • , M. Cremona
  • , C. Morgan
  • , S. Toomey
  • , A. Carr
  • , A. O’Grady
  • , B. T. Hennessy
  • , A. J. Eustace
  • Royal College of Surgeons in Ireland

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science